Fulcrum Therapeutics (NASDAQ:FULC) Shares Gap Up – Should You Buy?

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) shares gapped up before the market opened on Monday . The stock had previously closed at $9.85, but opened at $10.39. Fulcrum Therapeutics shares last traded at $9.65, with a volume of 83,455 shares changing hands.

Analysts Set New Price Targets

Several analysts have commented on the stock. The Goldman Sachs Group reaffirmed a “positive” rating on shares of Fulcrum Therapeutics in a research report on Monday, December 8th. HC Wainwright raised their price target on shares of Fulcrum Therapeutics from $18.00 to $25.00 and gave the stock a “buy” rating in a research note on Monday, December 8th. Royal Bank Of Canada upped their price objective on Fulcrum Therapeutics from $7.00 to $10.00 and gave the company a “sector perform” rating in a research note on Monday, December 8th. Bank of America increased their price objective on Fulcrum Therapeutics from $6.00 to $7.00 and gave the company an “underperform” rating in a report on Tuesday, December 9th. Finally, Truist Financial raised their target price on Fulcrum Therapeutics from $14.00 to $18.00 and gave the stock a “buy” rating in a research report on Thursday, December 11th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $19.11.

Fulcrum Therapeutics Trading Down 3.9%

The firm has a market cap of $512.23 million, a P/E ratio of -8.07 and a beta of 3.20. The stock’s fifty day moving average is $10.69 and its two-hundred day moving average is $8.77.

Fulcrum Therapeutics (NASDAQ:FULC) last released its quarterly earnings results on Wednesday, October 29th. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.02). On average, analysts forecast that Fulcrum Therapeutics, Inc. will post -0.16 EPS for the current year.

Insider Activity

In related news, major shareholder Ra Capital Management, L.P. sold 4,175,139 shares of the company’s stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $13.98, for a total value of $58,368,443.22. Following the transaction, the insider directly owned 6,053,960 shares in the company, valued at approximately $84,634,360.80. This represents a 40.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Robert J. Gould sold 15,000 shares of the business’s stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $11.87, for a total transaction of $178,050.00. Following the completion of the transaction, the director directly owned 469,864 shares of the company’s stock, valued at approximately $5,577,285.68. This represents a 3.09% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 4,205,139 shares of company stock valued at $58,711,943 in the last three months. 7.00% of the stock is owned by insiders.

Hedge Funds Weigh In On Fulcrum Therapeutics

Several institutional investors have recently modified their holdings of the company. Quarry LP purchased a new stake in Fulcrum Therapeutics in the third quarter worth approximately $35,000. Farther Finance Advisors LLC lifted its holdings in shares of Fulcrum Therapeutics by 108.3% in the 3rd quarter. Farther Finance Advisors LLC now owns 7,112 shares of the company’s stock worth $65,000 after acquiring an additional 3,697 shares during the last quarter. Russell Investments Group Ltd. boosted its stake in shares of Fulcrum Therapeutics by 4,209.3% in the 2nd quarter. Russell Investments Group Ltd. now owns 9,308 shares of the company’s stock valued at $64,000 after purchasing an additional 9,092 shares in the last quarter. Assetmark Inc. bought a new stake in Fulcrum Therapeutics in the third quarter worth $88,000. Finally, Y Intercept Hong Kong Ltd purchased a new stake in Fulcrum Therapeutics during the third quarter valued at about $104,000. 89.83% of the stock is currently owned by institutional investors.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.